Genomics in the Diagnosis, Classification, and Management of Myeloid and Lymphoid Neoplasms

A Georgetown University, Baylor College of Medicine,
and Genomic Testing Cooperative Symposium

Washington, DC April 26-27, 2024

Goldberg Auditorium on the Georgetown University Campus

Location: Goldberg auditorium, Gorman building, Ground floor - MedStar Georgetown University Hospital

3800 Reservoir Rd, Washington, D.C. 20007 

Learning Objectives

  • Introduction to the newest NGS innovations in hematology 
  • Clinical Application of NGS data in clinical practice with a focus on RNA 
  • The use of artificial intelligence in NGS RNA data analysis and clinical practice 
  • How advances in liquid biopsy technology are changing the practice of medicine 

April 26th

Genomics Workshop

Genomic and Translational Science
in Hematologic Diseases

  • Maher Albitar, MD – CEO/CMO, Genomic Testing Cooperative
  • Andre Goy, MD – Physician in Chief, Hackensack Meridian Health
  • Hong Zhong, Ph. D – Professor of Computer Science, Georgia Southern University 
  • Lacey Williams, MD – Georgetown University 
  • Paul Sackstein MD – Georgetown University 
  • Anne Renteria, MD, – Bone Marrow Transplant Director, Lombardi Cancer Institute. Georgetown University School of Medicine. 
  • Kieron Dunleavy, MD – Lombardi Cancer Institute. Georgetown University School of Medicine.
  • Ann-Kathrin Eisfeld, MD, Ohio State University 
  • Lea Cunnigham, MD, PhD, National Cancer Institute, NIH
  • Gustavo Rivero, MD, Georgetown University  
  • Kimberley Doucette, MD – Georgetown University

7-8:  Breakfast 
8-8:10: Welcoming remarks 

8:10-8:30: Clinical Applications of NGS (Albitar)

8:30-8:50: Artificial Intelligence in the clinical application of NGS data (Zhong)

8:50-9:10: Ex-vivo transcript deregulation in hemopoietic stem cell vs progenitors: Advancing Next Generation Sequencing Applicability– Tiphaine C. Martin. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York.

9:10-9:40:

“Bioinformatic Signatures in Molecular Diagnostics”

9:40-10:00: Clinical applications of NGS in Myeloid Malignancies (Ann-Kathrin Eisfeld), Ohio State University 
10:00-10:20: NGS in AML (Albitar and Lacey Williams) 
10:20-10:40: NGS in MDS and MPN (Albitar and Andrew Tiu)  
10:40-10:50: Break  

10:50-11:10: Germline Predisposition Syndromes (Lea Cunnigham), The Role for BMT. National Institute of Health 
11:10-11:30: NGS and Measurable Residual Disease (MRD) (Anne Renteria) Lombardi Cancer Institute, Georgetown University  
11:30-11:50: Could NGS Guide GVHD prophylaxis? (Lacey Williams) Lombardi Cancer Institute, Georgetown University  

11:50-12:20:  Integrating NGS and Donor/Recipient Chimerism to Inform Relapse Risk and Post BMT Complications.  
(Renteria, Olga Timofeva, Ala Ali, Albitar).  

12:20 pm – 1:30 pm  

1:30-1:50: Lymphoma treatment decisions based on molecular data (Goy) Hackensack Meridian Health 
1:50-2:10: Lymphoma diagnosis using NGS data and artificial Intelligence (Maher Albitar) 
2:10-2:30: Molecular monitoring of lymphoma (Kieron Dunleavy) Lombardi Cancer Institute, Georgetown University  
2:30-2:50: Case presentation (Mycal Casey and Maher Albitar) 

3:00-3:20- Myeloma Molecular Diagnosis and Risk Stratification (Doucette)
3:20-3:30- Myeloma advances by using NGS data and artificial Intelligence (Albitar)
3:30-4:00- Case presentation (Williams and Albitar).

April 27th

6th Myeloid Malignancies Symposium

Genomic and Clinical Science 
in Hematologic Diseases

  • Sidd Jaiswal, MD, Ph.D, BS, 
    Stanford Medicine Children’s Health, California, USA 
  • Caroline Watson  
    Early Cancer Institute, University of Cambridge, Cambridge Biomedical Campus, Cambridge, Cambridgeshire, UK 
  • Michelle Machiela, MD, 
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA. 
  • George S. Vassiliou, MD, Ph.D,  
    Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK 
  • David Salman, MD  
    Lee Moffit Cancer Center, Tampa Florida, USA
  • Amy Desern MD, MHS
    The Johns Hopkins University School of Medicine, Baltimore, USA   
  • Hetty Carraway, MD, MBA  
    Cleveland Clinic, OH, USA 
  • Guillermo Garcia Manero  
    MD Anderson Cancer Center, Houston, USA
  •  Pedro Padron, MD,  
    Lee Moffit Cancer Center, Tampa Florida, USA 
  • Mrinal Paknaik, MD,  
    Division of Oncology Research, Mayo Clinic, Rochester, MN, USA
  • Mikkael A. Sekeres MD,  
    Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA 
  • Gustavo Rivero, MD, 
    Georgetown University School of Medicine. USA
  • Christoph Rollig, MD,  
    The University Hospital Carl Gustav Carus, Dresden, Germany  
  • Naval Daver, MD,  
    MD Anderson Cancer Center, Houston, USA
  • Christopher Hourigan MD, Ph.D, National Institute of Health, Maryland, USA
  • Craig Kessler, MD, 
    Georgetown University School of Medicine, USA
  • Ang Li, MD,  
    Baylor College of Medicine, Houston, USA
  • Romina Sosa, MD, Ph.D,  
    Fox Chase Cancer Center, Philadelphia, USA
  • Srdan Verstovsek, MD, Ph.D,  
    The University of Texas, MD Anderson Cancer Center, Houston, USA
  • Anne Renteria, MD,  
    Georgetown University School of Medicine, USA
  • Sergio Rutella, MD,  
    John Van Geest Cancer Research  
    Centre, Nottingham Trent University, Nottingham, United Kingdom
  • Mohamad Mohty MD,  
    Hematology and Cellular Therapy Department, Hôpital Saint-Antoine, and Université Pierre & Marie Curie, Paris, France
  • Silviu Itescu, MD, 
    CEO of Mesoblast, USA 
  • Gail Roboz, MD,  
    Director of the Clinical and Translational Leukemia Programs 
    Weill Medical College of Cornell University, USA
  • Terry Fry, MD, 
    Vice President, Head of T Cell Therapeutics, Sana Biotechnology, USA

*Speakers subject to change

8-8:05 am: Welcome  
Chair and Section Moderators  

Molecular Basis of Clonal Hematopoiesis  
“From Clinical Observations to Bench” 
Section moderator: Sidd Jaiswal, M.D., Ph.D., BS., 
Stanford Medicine Children’s Health, California, USA 

8:05- 8:30 am Featured Lecture: “Leveraging to understand myeloid mutation fitness.” 
Speaker: Caroline Watson  
Early Cancer Institute, University of Cambridge, Cambridge Biomedical Campus, Cambridge, Cambridgeshire, UK 

8:30-9:15 am “Mid-Atlantic Clonal Hematopoiesis Tumor Board”  
Case and Precision Medicine Discussion   

  • Sidd Jaiswal, M.D., Ph.D., BS., 
    Stanford Medicine Children’s Health, California, USA
  • Michelle Machiela, M.D., 
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
  • George S. Vassiliou, M.D., Ph.D.,  
    Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK 

Myelodysplasia  
Section Moderator: David Salman, M.D.  
Lee Moffit Cancer Center, Tampa Florida  

9:15-9:35 am Current Status of P53 Targeted Therapy in MDS  
Speaker: Amy Desern M.D., M.H.S. 
The Johns Hopkins University School of Medicine, Baltimore, USA  

9:35-9:55 am  Innovative approach for management of hypomethylating agent failure 
Speaker: Hetty Carraway, M.D., MBA.  
Cleveland Clinic, OH, USA

9:55-10:10 am  New TGF-beta inhibitor indications 
Speaker: Guillermo Garcia Manero  
MD Anderson Cancer Center, Houston, USA 

Chronic Myelomonocytic Leukemia  
Section Moderator: Pedro Padron, M.D.,  
Lee Moffit Cancer Center, Tampa Florida 

10:10-10:40 am “Mid-Atlantic MDS/CMML Tumor Board”  
Case and Innovative Therapies Discussion  

  • Mrinal Paknaik, M.D.,  
    Division of Oncology Research, Mayo Clinic, Rochester, MN, USA 
  • Mikkael A. Sekeres M.D.,  
    Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA 

10:40-10:50  Coffe Break

Acute Myelogenous Leukemia  
Section Moderator: Gustavo Rivero, M.D., 
Georgetown University School of Medicine 

10:50-11:10 am Newer AML targeted therapies  
 Speaker: Christoph Rollig, M.D.,  
The University Hospital Carl Gustav Carus, Dresden, Germany 

11:15-11:35 am  Liposomal cytarabine/Daunorubicin vs HMA+ Venetoclax  
“How to decide” 
 Speaker: Naval Daver, M.D.,  
MD Anderson Cancer Center, Houston, USA  

11:40-12:00 pm How to optimize your patient for allogeneic transplantation- “New evolving Measurable residual disease concepts” 
Speaker: Christopher Hourigan M.D., Ph.D., National Institute of Health, Maryland, USA 

Noon Theater A 
12- 12:30 pm  
“Advancing Sequencing: Transcriptomic Immunophenotyping” 
Genomic Testing Cooperative, Tempus, GenPath technology  

Noon Theater B 
1230-1pm  
 Quizartinib vs Midostaurin in the Upfront Therapy of FLT3 AML 
Novartis, Daiichi 

Myeloproliferative Neoplasms 
Section Moderator: Craig Kessler, M.D., 
Georgetown University School of Medicine 

12:00- 1:20 pm  New Molecular Discoveries in MPN that Explain Thrombosis Risk 
Speaker: Ang Li, M.D.,  
Baylor College of Medicine, Houston, USA   

1:20-1:40 pm Advances in the therapy of Polycythemia Vera. 
Speaker: Romina Sosa, M.D., Ph.D.,  
Fox Chase Cancer Center, Philadelphia, USA

1:40-2:00 pm  Novel JAK inhibitor therapies 
Speaker: Srdan Verstovsek, M.D., Ph.D.,  
The University of Texas, MD Anderson Cancer Center, Houston, USA 

Biologic and Cellular Therapy for Myeloid Disorder 
Section Moderator: Anne Renteria, M.D.,  
Georgetown University School of Medicine  

2:10-2:30 pm  Newer Bispecific Antibodies  
Speaker: Sergio Rutella, M.D.,  
John Van Geest Cancer Research  
Centre, Nottingham Trent University, Nottingham, United Kingdom 

2:35-3:00 pm Haplo vs MUD donor transplantation for high-risk AML?  
 Speaker Mohamad Mohty M.D.,  
Hematology and Cellular Therapy Department, Hôpital Saint-Antoine, and Université Pierre & Marie Curie, Paris, France 

3:05-3:25 pm  Newer Intervention to Mitigate GVHD 
Speaker: Silviu Itescu, M.D., 
CEO of Mesoblast 

3:30-3:55 pm  Advances in CART for AML  
Speaker: Gail Roboz, M.D.,  
Director of the Clinical and Translational Leukemia Programs 
Weill Medical College of Cornell University  

3:55- 4:20 pm  Innovative Cell Therapy Trials  
Speaker: Terry Fry, M.D., 
Vice President, Head of T Cell Therapeutics, Sana Biotechnology 

4:25-4:30 pm  Abstracts Awards  

4:30-4:35 pm  

4:30-4:35 pm  Announcement –MyeloHub Genomic Consortium  
[Georgetown University-Hackensack University and Baylor College of Medicine]  

4:35-4:40 pm  Final Remarks- 2025 Event Promotion –  

About The Location

Get Directions

Goldberg auditorium, Gorman building, Ground floor.

MedStar Georgetown University Hospital

3800 Reservoir Rd

Washington, D.C. 20007 

Housing